TransThera
Nanjing
China
About TransThera
TransThera Biosciences Co. Ltd, a startup biotech company specialized in developing novel NCE drugs. TransThera will adopt a novel business model to adapt open innovation. Its current portfolio covers disease areas such as oncology, cardiovascular diseases and more.
LEADERSHIP:
Founder and CEO: Frank Wu
7 articles about TransThera
-
TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency
3/8/2024
TransThera today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus physician's choice to evaluate the efficacy and safety in subjects with FGFR-altered, chemotherapy- and FGFR Inhibitor-refractory/relapsed cholangiocarcinoma (CCA).
-
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma
12/21/2023
TransThera today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420).
-
TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma
11/3/2021
TransThera Sciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinoma (CCA) who have no standard treatment options.
-
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure
12/17/2019
TransThera Biosciences Co. Ltd announced that the U.S. Food and Drug Administration has granted the company's Investigational New Drug application for TT-00920, a novel small molecule inhibitor of Phosphodiesterase 9 for the treatment of chronic heart failure.
-
TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma
11/7/2019
TransThera Biosciences Co. Ltd, announced that company received Orphan Drug Designation from US Food and Drug Administration for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma.
-
TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
9/28/2018
TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).
-
TransThera Biosciences Closes Round A Financing To Develop Novel NCE Drugs
10/14/2016